Like Replica Analytics Ltd.

closed 1/5/2022 via PR Newswire

Aetion, Inc., acquired Replica Analytics Ltd.

synopsis: Aetion, the leading regulatory-grade real-world evidence technology provider, has acquired Ontario-based Replica Analytics, a pioneer in using AI for synthetic health data generation. Replica's AI technology generates synthetic, privacy-protected copies of real-world data that preserve the integrity and utility of source data.
buyer parent: New Enterprise Associates
buyer: Aetion, Inc.
Aetion is a healthcare analytics company. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. "
target: Replica Analytics Ltd.
Based in Ontario, Replica Analytics is a developer of unique technologies for generating privacy protective synthetic data that maintains the statistical properties of real data. Its Replica Synthesis software provides a full suite of synthetic data generation and evaluation capabilities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/7/2021 via BusinessWire

W2O Group, acquired Swoop and IPM.ai

synopsis: W2O, a digital-first healthcare marketing agency, has acquired Swoop and IPM.ai, pioneers in using AI to solve big challenges in healthcare. Swoop provides precision healthcare marketing services for pharmaceutical companies. IPM.ai is an Insights as a Service provider that empowers life sciences companies to better understand their patients.
buyer parent: New Mountain Capital, LLC
buyer: W2O Group
W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place. Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. "
target: Swoop and IPM.ai
Swoop and IPM.ai are pioneers in using AI to solve big challenges in healthcare. Swoop provides precision healthcare marketing services for pharmaceutical companies. IPM.ai is an Insights as a Service provider that empowers life sciences companies to better understand their patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/13/2019 via BNC Analysis

IQVIA, acquired Linguamatics Limited

synopsis: Health analytics and contract research heavyweight IQvia has acquired bioinformatics company Linguamatics. Linguamatics delivers market-leading Natural Language Processing (NLP) based AI solutions for high-value knowledge discovery and decision support from text.
buyer: IQVIA (NYSE:IQV:$10,412.00)
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. "
target: Linguamatics Limited
Linguamatics delivers market-leading Natural Language Processing (NLP) based AI solutions for high-value knowledge discovery and decision support from text. They empower their customers to speed up drug development and improve patient outcomes.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/23/2017 via PR Newswire

Chan Zuckerberg Initiative, will acquire Meta Inc.

synopsis: iGan Partners announced the pending acquisition of its portfolio company, Meta, by the Chan Zuckerberg Initiative. Meta uses artificial intelligence to read the world's scientific papers, understand what is in them, and deliver their insights to researchers in real time.
buyer: Chan Zuckerberg Initiative
The Chan Zuckerberg Initiative was launched by Facebook founder and CEO Mark Zuckerberg and Dr. Priscilla Chan, pediatrician and founder of the Primary School. CZI seeks to advance human potential and promote equality. "
target parent: iGan Partners
target: Meta Inc.
Toronto-based tech company Meta helps researchers understand what is happening globally in science, and shows them where science is headed. Meta uses artificial intelligence to read the world's scientific papers, understand what is in them, and deliver their insights to researchers in real time.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/25/2021 via BNC Analysis

Immunai, acquired Dropprint Genomics

synopsis: Immunai, a biotech company using single-cell biology and AI to power new therapeutic discoveries, has acquired Dropprint Genomics, a single-cell genomics software company. Dropprint develops software for doing data driven drug discovery in immunological diseases using single cell genomics and machine learning.
buyer: Immunai
Immunai is a biotech company using single-cell biology and AI to power new therapeutic discoveries. Immunai’s end-to-end single-cell platform enables high resolution profiling of the immune system at industrial scale, generating biological insights that accelerate R&D and power novel discoveries. "
target: Dropprint Genomics
Dropprint Genomics is a single-cell genomics software company. Dropprint develops software for doing data driven drug discovery in immunological diseases using single cell genomics and machine learning. Their technology identifies gene data sets to help users better understand the immune system.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2020 via Company Press Release

Phlexglobal, acquired Cunesoft

synopsis: Phlexglobal, the leading provider of Trial Master File (TMF) software and expert services, has acquired Cunesoft, a European leader in cloud-based regulatory software solutions for the life sciences industry. Cunesoft offers a machine learning powered regulatory compliance software suite for compliant document, data and submission management.
buyer parent: Vitruvian Partners LLP
buyer: Phlexglobal
Phlexglobal is the world-leading specialist provider of electronic Trial Master File (eTMF) systems and services to the life sciences industry. Phlexglobal leverages authoritative TMF technologies and expert services to bring order, stability, and control to their client's Trial Master File. "
target: Cunesoft
Cunesoft is a European leader in cloud-based regulatory software solutions and services for all segments within the life sciences industry. Cunesoft offers a machine learning powered regulatory compliance software suite for compliant document, data and submission management.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$5,318.32)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 12/23/2015 via BusinessWire

QPharma, Inc., acquired Qforma, Inc.

synopsis: QPharma, a premier provider of compliance and commercial services to the life sciences industry, announced the acquisition of Qforma, Inc. Qforma offers an array of life sciences solutions that include healthcare analytics, predicitive modeling, and product launch services.
buyer: QPharma, Inc.
QPharma provides a suite of solutions to the life sciences industry. Services offered by the company’s Professional Services division include validation services, project management, auditing, and training. "
target parent: BelHealth Investment Partners
target: Qforma, Inc.
Qforma is a leading provider of social analytics for the life sciences industry. Based on advanced data and analytics, Qforma helps its clients to understand, monitor and predict behavior in all relevant communities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/15/2014 via PR Web

Cision AB, Vocus, Inc., acquired Visible Technologies

synopsis: Vocus, Inc. and Cision, leading global providers of cloud-based public relations software have been brought together by private equity firm GTCR, announced the acquisition of Visible Technologies. Visible is a worldwide market leader in social media listening and analytics, insights and engagement.
buyer: Cision AB (:$739.91)
buyer: Vocus, Inc.
Vocus is a leading provider of public relations software that enables professionals to plan, execute and measure influencer-oriented campaigns in one integrated platform. Cision is a leading provider of cloud-based PR software, services and tools for the marketing and public relations industry. "
target: Visible Technologies
Visible Technologies is the leader in social media monitoring, analytics, and services for enterprises globally. Visible helps businesses analyze social media conversations to better understand consumer preferences, market dynamics, competitive strengths and weaknesses, and other information.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/6/2013 via PR Newswire

Qforma, Inc. merged with SkilaMederi,

synopsis: SkilaMederi, a global life-sciences social analytics strategic solutions and launch optimization provider, and Qforma, a leading provider of advanced analytics and predictive technologies for the life sciences industry, announce their merger.
buyer parent: BelHealth Investment Partners
buyer: SkilaMederi
SkilaMederi is a leading provider of global product launch optimization and stakeholder engagement insight that drive measurable value for life sciences companies. SkilaMederi serves medical, marketing, market access and sales teams at pharmaceutical, biotechnology and medical device companies. "
target: Qforma, Inc.
Qforma empowers its healthcare customers with actionable insights, quantified metrics, and timely alerts to impending change. Qforma is a leader in Community Opinion Leader mapping, which is critical as healthcare companies continue to educate physicians about new therapies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/21/2020 via PR Newswire

Elsevier B.V., acquired SciBite

synopsis: Elsevier, a global research publishing and information analytics provider, and part of RELX, has acquired SciBite, a semantic AI company headquartered in Cambridge, UK, to help customers make faster, more effective R&D decisions through advanced text and data intelligence solutions.
buyer parent: RELX Group plc
buyer: Elsevier B.V.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers and tackle human crises. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education. "
target: SciBite
SciBite offer a complete semantic services platform for life sciences that can be used as a data analytics solution by end users and also as a 'pluggable' component to transform existing IT infrastructures into more scientifically aware systems.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/21/2018 via Company Press Release

Melissa, acquired IO Informatics, Inc.

synopsis: Melissa, a leading provider of global contact data quality and identity verification solutions, launched Melissa Informatics, fueled by its acquisition of semantic technology firm, IO Informatics (IOI). IOI’s software and services support global leaders in life sciences, reducing time and cost to benefit from clean, richly connected data.
buyer: Melissa
Melissa provides identity verification and contact data quality for over 10,000 customers worldwide, helping profile, cleanse, update, match and enrich People Data to prevent fraud, decrease costs, drive revenue and improve customer communications. "
target: IO Informatics, Inc.
Semantic technology firm, IO Informatics (IOI), provides software and services to support global leaders in life sciences, biotechnology, pharmaceutical, and medical industries, reducing time and cost to benefit from clean, richly connected data.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/28/2015 via BusinessWire

Expert System S.p.A., will acquire TEMIS S.A.

synopsis: Expert System, the leader in semantic technology for the effective management of unstructured information, announced an agreement to acquire TEMIS, a leader in text analytics solutions. With the acquisition of TEMIS, Expert System will become the leading global provider of semantic technology for cognitive computing.
buyer: Expert System S.p.A. (:$13.44)
Expert System is a provider of information access solutions based on the proprietary, patented technology of Cogito. Expert System's products provide enterprise companies the ability to go beyond traditional keyword approaches for the rapid sense-making of their structured and unstructured data. "
target: TEMIS S.A.
TEMIS helps organizations structure, manage and leverage their unstructured information assets. Its flagship platform, Luxid®, identifies and extracts targeted information to semantically enrich content with domain-specific metadata.
price ($mm)
$13
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/13/2017 via PR Newswire

SciBite, acquired FactBio Ltd

synopsis: SciBite, a firm whose technology is revolutionising R&D for pharmaceutical companies across the globe, has acquired Cambridge based FactBio, a leading developer of semantic software for data management and curation for the life sciences.
buyer: SciBite
SciBite offer a complete semantic services platform for life sciences that can be used as a data analytics solution by end users and also as a 'pluggable' component to transform existing IT infrastructures into more scientifically aware systems. "
target: FactBio Ltd
FactBio is a leading developer of semantic software for data management and curation for the life sciences. FactBio builds ontologies and tools for the curation and management of scientific data. The company's focus is on biomedical data, with the potential to apply its tools more widely.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/1/2015 via BNC Analysis

Aurea, acquired NextDocs Corporation

synopsis: NextDocs, a global leader in providing Microsoft SharePoint-based compliance solutions to life sciences organizations, was acquired by Aurea Software. NextDocs provides solutions for managing regulatory documents, SOPs, and clinical documents, as well as a full set of quality processes from CAPA to complaints.
buyer parent: ESW Capital, LLC
buyer: Aurea
Aurea enables companies to deliver transformative customer experiences. Their Customer Experience Platform helps customers build, execute, monitor and optimize the customer journey for a diverse range of industries including energy, retail, insurance, travel and hospitality, and life sciences. "
target: NextDocs Corporation
NextDocs is the global leader in compliance innovation for life sciences organizations. NextDocs provides solutions for managing regulatory documents, SOPs, and clinical documents, as well as a full set of quality processes from CAPA to complaints.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/30/2013 via BusinessWire

IMS Health Incorporated, acquired Semantelli

synopsis: IMS Health announced the acquisition of Semantelli Corporation, a Bridgewater, N.J.-based social media analytics company, to extend its marketing and consumer engagement capabilities for healthcare organizations around the world. Semantelli offers cloud-based tools that automate the collection of healthcare-specific social media content.
buyer parent: TPG Capital
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading worldwide provider of information, technology, and services dedicated to making healthcare perform better. The IMS global technology infrastructure, advanced analytics and proprietary software platforms help clients improve patient outcomes and operate more efficiently. "
target: Semantelli
Semantelli’s solutions for global life sciences and healthcare companies address compliance needs in social media, guide marketing activities and identify new real-time opportunities with insights gleaned from social media.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/21/2016 via BNC Analysis

A Consortium of 4 Buyers purchased a minority stake in Transcriptic

synopsis: Transcriptic Inc., a robotic cloud laboratory for life sciences, has announced the closing of a Series A-1 investment. The new funding was led by Data Collective, along with new investors Digital Science and WuXi AppTec. Existing investors, including AME Cloud Ventures, and others also contributed to the round.
buyer: Digital Science
buyer: Wuxi AppTec (WX:$640.80)
buyer: Data Collective
buyer: AME Cloud Ventures
Digital Science provides software to support researchers. Data Collective is a venture capital fund. WuXi AppTec is a global pharmaceutical and medical device open-access capability and technology platform. AME Cloud Ventures is the early stage fund of Jerry Yang, Yahoo's founder. "
target: Transcriptic
Transcriptic is building a revolutionary laboratory virtualization platform: "cloud computing" for the life sciences. They've developed machine-readable protocol and robotics technology for carrying out experiments quickly, cheaply, and highly repeatably.
price ($mm)
$13
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/23/2020 via BusinessWire

Curi Bio, acquired Dana Solutions

synopsis: Curi Bio has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
buyer: Curi Bio
Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. "
target: Dana Solutions
Dana Solutions is a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/24/2020 via GlobeNewswire

Predictive Oncology Inc., will acquire Quantitative Medicine

synopsis: Predictive Oncology Inc. , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is to acquire Quantitative Medicine, a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE.
buyer: Predictive Oncology Inc. (POAI:$1.38)
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. "
target: Quantitative Medicine
Quantitative Medicine is a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/14/2009 via BusinessWire

Eliza Corporation, acquired Sprigley

synopsis: Eliza Corporation, the leading provider of integrated healthcare communication strategies, announced that it has completed the acquisition of Sprigley, developer of a multi-channel recommendation engine and social networking platform designed specifically for use in the healthcare industry.
buyer: Eliza Corporation
Eliza Corporation blends technology, communication expertise, and data analytics to drive healthy behavior change. The company’s intelligent, tailored interactions—including automated calls—make health and healthcare information more accessible, more actionable, and more engaging. "
target: Sprigley
Sprigley is a developer of a multi-channel recommendation engine and social networking platform designed specifically for use in the healthcare industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/5/2022 via PR Newswire

Aetion, Inc., acquired Replica Analytics Ltd.

synopsis: Aetion, the leading regulatory-grade real-world evidence technology provider, has acquired Ontario-based Replica Analytics, a pioneer in using AI for synthetic health data generation. Replica's AI technology generates synthetic, privacy-protected copies of real-world data that preserve the integrity and utility of source data.
buyer parent: New Enterprise Associates
buyer: Aetion, Inc.
Aetion is a healthcare analytics company. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. "
target: Replica Analytics Ltd.
Based in Ontario, Replica Analytics is a developer of unique technologies for generating privacy protective synthetic data that maintains the statistical properties of real data. Its Replica Synthesis software provides a full suite of synthetic data generation and evaluation capabilities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/5/2022 via PR Newswire

Aetion, Inc., acquired Replica Analytics Ltd.

synopsis: Aetion, the leading regulatory-grade real-world evidence technology provider, has acquired Ontario-based Replica Analytics, a pioneer in using AI for synthetic health data generation. Replica's AI technology generates synthetic, privacy-protected copies of real-world data that preserve the integrity and utility of source data.
buyer parent: New Enterprise Associates
buyer: Aetion, Inc.
Aetion is a healthcare analytics company. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. "
target: Replica Analytics Ltd.
Based in Ontario, Replica Analytics is a developer of unique technologies for generating privacy protective synthetic data that maintains the statistical properties of real data. Its Replica Synthesis software provides a full suite of synthetic data generation and evaluation capabilities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/1/2017 via BusinessWire

Simulations Plus, Inc., acquired DILIsym Services, Inc.

synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that it has acquired DILIsym Services, Inc, the leading provider of drug-induced liver injury simulation software and related consulting services to the pharmaceutical industry.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. "
target: DILIsym Services, Inc.
DILIsym Services, Inc. was founded in 2015 in Research Triangle Park, North Carolina, and is the leading provider of drug-induced liver injury simulation software and related consulting services to the pharmaceutical industry.
price ($mm)[EV]
$4.50 [$5.00]
rev ($mm)
$3
EBITDA ($mm)
EV / rev
3.3x
EV / EBITDA
announced 3/13/2012 via BusinessWire

Certara, will acquire Simcyp Limited

synopsis: Certara has announced the completion of its acquisition of UK-based Simcyp Limited. Simcyp is a leading research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations, including pediatric populations.
buyer parent: Vector Capital
buyer: Certara (:$261.77)
Certara™ is dedicated to improving human health through a broad spectrum of software products and services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. "
target parent: Fusion IP plc
target: Simcyp Limited
Simcyp provides platforms for the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual human populations and virtual laboratory animals (rat, dog and mouse).
price ($mm)
$32
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/3/2008 via BusinessWire

Tripos, Inc., acquired Pharsight Corporation

synopsis: Tripos International, the leading provider of drug discovery informatics products and services, today announced that it has completed the acquisition of Pharsight Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development.
buyer parent: Vector Capital
buyer: Tripos, Inc.
Tripos combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. "
target: Pharsight Corporation (PHST:$28.34)
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
price ($mm)[EV]
$52 [$36]
rev ($mm)
$28
EBITDA ($mm)
$2
EV / rev
1.4x
EV / EBITDA
17.8x
closed 5/1/2006 via BusinessWire

PerkinElmer, Inc., acquired Spectral Genomics, Inc.

synopsis: PerkinElmer, Inc., a global technology leader in Health Sciences and Photonics, today announced the acquisition of the assets of Spectral Genomics, Inc., a leader in molecular karyotyping technology used to evaluate chromosomal abnormalities. Terms of the deal were not disclosed.
buyer: PerkinElmer, Inc. (PKI:$2,209.40)
PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. "
target: Spectral Genomics, Inc.
Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders.
price ($mm)
$12
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/28/2020 via BusinessWire

Recursion Pharmaceuticals, Inc., acquired Vium, Inc.

synopsis: Recursion, a digital biology™ company leading in the industrialization of drug discovery, has announced its acquisition of Vium, a digital vivarium™ company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research.
buyer: Recursion Pharmaceuticals, Inc.
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, AI, machine learning, in vivo validation capabilities and a highly cross-functional team to discover novel medicines that expand our collective understanding of biology. "
target: Vium, Inc.
Vium is the first company to create a fully digital end to end Digital Vivarium® platform which is transforming in vivo research. The Vium Digital Vivarium, Vium Cloud, and online Research Suite empower scientists to optimize advances in bioengineered research models in ways previously not possible.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/23/2020 via BusinessWire

Curi Bio, acquired Dana Solutions

synopsis: Curi Bio has acquired Dana Solutions, a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
buyer: Curi Bio
Curi Bio provides a seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. "
target: Dana Solutions
Dana Solutions is a pioneer in the application of artificial intelligence and machine learning to in vitro cell-based assays. They offer state-of-the-art AI products for drug screening, toxicity testing, and quality control.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/2/2020 via BusinessWire

Simulations Plus, Inc., acquired Lixoft

synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, has acquired Lixoft of Paris, France. Lixoft designs software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus is a premier developer of drug discovery and development software and is a provider of preclinical and clinical pharmacometric consulting services for regulatory submissions. The company also provides quantitative systems pharmacology models for liver-related injury and disease. "
target: Lixoft
Paris-based Lixoft designs software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. The company's Monolix Suite is a leading provider of population PKPD (Pharmacokinetic/Pharmacodynamic) modeling for pharmacometricians.
price ($mm)
$11
rev ($mm)
$4
EBITDA ($mm)
EV / rev
4.7x
EV / EBITDA
announced 1/24/2020 via GlobeNewswire

Predictive Oncology Inc., will acquire Quantitative Medicine

synopsis: Predictive Oncology Inc. , a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is to acquire Quantitative Medicine, a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE.
buyer: Predictive Oncology Inc. (POAI:$1.38)
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. "
target: Quantitative Medicine
Quantitative Medicine is a biomedical analytics and computational biology company that has developed a novel, computational drug discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/15/2019 via BusinessWire

Instem, acquired Leadscope, Inc.

synopsis: Instem, a leading provider of IT solutions to the global life sciences market, announced that it has acquired Leadscope, a company that builds a chemoinformatics platform. Using Leadscope, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques.
buyer: Instem (AIM:INS:$38.90)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
target: Leadscope, Inc.
Leadscope builds a chemoinformatics platform. As a suite of tools, researchers have integrated access to chemistry-based data mining, visualization and advanced informatics techniques (prediction tools, scaffold generators, etc.).
price ($mm)
$4.10
rev ($mm)
$2
EBITDA ($mm)
$0
EV / rev
2.4x
EV / EBITDA
11.5x
closed 9/13/2018 via BusinessWire

Certara, acquired Pirana Software

synopsis: Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence solutions, announced that it has acquired Pirana, a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
buyer parent: Arsenal Capital Partners
buyer: Certara (:$261.77)
Certara enables superior drug development and patient care decision-making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration. "
target: Pirana Software
Pirana is a widely used product for connecting and organizing pharmacometric modeling results as well as providing interfaces to a range of software tools used in pharmacometrics modeling.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2016 via Company Press Release

C4X Discovery, acquired Adorial

synopsis: C4X Discovery, a company that aims to become the world’s most productive drug discovery and development company, has acquired Adorial, a privately held drug discovery company with a proprietary genetic technology platform for the identification of novel drug targets.
buyer: C4X Discovery (AIM:C4XD:$0.44)
C4X Discovery aims to become the world’s most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. "
target: Adorial
Adorial's key genetic technology, Taxonomy3® is a novel in silico platform technology that utilises proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data.
price ($mm)
$2.36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2013 via Yahoo, Inc.

Elsevier B.V., acquired Aureus Sciences

synopsis: Elsevier announced the acquisition of Aureus Sciences, a Paris, France based privately held company that provides databases and information tools to pharmaceutical and biotech companies. Aureus Sciences gathers unique and high quality quantitative biological activity data for major therapeutic drug targets.
buyer parent: Reed Elsevier
buyer: Elsevier B.V.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles. "
target: Aureus Sciences
Aureus Sciences provides scientific databases and software applications for researchers involved in the drug discovery and development process.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/3/2012 via BusinessWire

CLC bio A/S, acquired Molegro

synopsis: CLC bio announced the acquisition of Molegro, a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
buyer: CLC bio A/S
CLC bio is the world's leading bioinformatics solution provider and the only one that provides both desktop and server software seamlessly integrated and optimized for best performance. The company is headquarted in Aarhus, Denmark. "
target parent: Østjysk Innovation A/S
target: Molegro
Founded in 2005, Molegro is a specialized software company focusing on molecular docking, including prediction and analysis of protein-ligand interactions, screening of compound databases for activities against a receptor, and determination of molecule similarity.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/1/2021 via BNC Analysis

Astorg, Nordic Capital, acquired Cytel Inc.

synopsis: Nordic Capital, a Swedish private equity investor, and Astorg, a French private equity firm, have acquired Cytel Inc. from New Mountain Capital. Cytel is one of the largest providers of statistical software and advanced analytics for clinical trial design and biometrics execution.
buyer: Astorg
buyer: Nordic Capital
Nordic Capital is a Swedish private equity investor with a commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Paris-based Astorg is a leading independent private equity firm with over €9 billion of assets under management. "
target parent: New Mountain Capital, LLC
target: Cytel Inc.
Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution. Its experts deliver industry-leading software, data-driven analytics, real-world evidence, and strategic consulting.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2014 via BusinessWire

Cognigen Corporation merged with Simulations Plus, Inc.,

synopsis: Simulations Plus, Inc., a leading provider of simulation and modeling software for pharmaceutical discovery and development, announced that the Agreement and Plan of Merger with Cognigen Corporation has been closed. Cognigen Corporation was founded in 1993 and has grown to become one of the leading providers of clinical trial data analysis.
buyer: Simulations Plus, Inc. (SLP:$35.84)
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. "
target: Cognigen Corporation
Cognigen Corporation is one of the leading providers of clinical trial data analysis. The company provides analysis and reports that are tailored to the expectations of regulatory agencies so that reports are submitted in a manner that minimizes follow-up questions from regulators.
price ($mm)
$5.20
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 2/6/2014 via BNC Analysis

Berry Consultants, LLC, will purchase FACTS from Tessella Ltd.

synopsis: Berry Consultants, a statistical consulting company specializing in the Bayesian approach to medical statistics, has reached an agreement with Tessella to acquire 100% ownership of FACTS. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market.
buyer: Berry Consultants, LLC
Berry Consultants is a statistical consulting company specializing in the Bayesian approach to medical statistics, an approach that is radically changing the way research is done throughout both device and drug development. "
seller: Tessella Ltd.
FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market. It allows biostatisticians and clinical teams to rapidly design and compare innovative, advanced, clinical trial designs.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/8/2014 via PR Newswire

Evidera, acquired Archimedes, Inc.

synopsis: Symphony Technology Group (STG), a technology and services-focused private equity firm, and Evidera, a leading provider of evidence-based solutions for the healthcare industry, announced the acquisition of Archimedes, a San Francisco-based healthcare modeling company and wholly owned subsidiary of Kaiser Permanente.
buyer parent: Symphony Technology Group
buyer: Evidera
Evidera provides health economics, outcomes research, market access, data analytics and epidemiology services. Their research and consulting services are driven by world-class science and thought leadership and leverage a unique combination of capabilities. "
target parent: Kaiser Permanente
target: Archimedes, Inc.
Archimedes is a healthcare modeling and analytics organization. With the Archimedes Model at its core, the company enables people to combine real-world healthcare data and simulation data to create compelling and actionable evidence used in individual healthcare decision making.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/27/2013 via PR Newswire

Temis Text Intelligence, acquired i3 Analytics

synopsis: TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, announced that they have acquired the US-based i3 Analytics. i3 Analytics provides the award-winning Biopharma Navigator, a Software-as-a-Service platform that charts the biopharma landscape based on Life Sciences open data.
buyer: Temis Text Intelligence
In order to develop and market innovative Text Mining Solutions, TEMIS was founded in September 2000 by a team of managers, researchers and consultants from IBM. This skilled team had earlier developed and distributed IBM Text Mining solutions worldwide "
target: i3 Analytics
i3 Analytics is a provider of advanced data analytics and visualization technologies. Their Biopharma Navigator is an analytics tool that allow users to map clinical trials landscapes, scan the horizon for the latest news, and stay current on what researchers are doing.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/22/2009 via BusinessWire

Phase Forward, acquired Waban Software

synopsis: Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, announced that it has acquired privately held Waban Software, a leading provider of platform solutions for the automation and compliance of clinical data analysis and reporting, for $14 million in cash.
buyer: Phase Forward (PFWD:$0.00)
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company offers proven solutions for electronic data capture, clinical data management and clinical data analysis and reporting automation and compliance. "
target: Waban Software
Waban Software provides solutions that enable pharmaceutical and biotechnology companies to capture, integrate, manage and analyze life-sciences and clinical trial data.
price ($mm)
$12
rev ($mm)
$4
EBITDA ($mm)
EV / rev
3.5x
EV / EBITDA
closed 11/12/2008 via BusinessWire

JNetDirect, Inc., acquired Sunergia Group, Inc.

synopsis: JNetDirect Inc. announced the acquisition of Sunergia Group Inc. and its better known operating unit, Sunergia Medical (www.sunergiamedical.com). Sunergia, a privately owned supplier of software and lab equipment to the biotech market, will now be renamed JNetDirect Biosciences.
buyer: JNetDirect, Inc.
JNetDirect is an innovative leader in software products for improving our customer's connectivity, integration, management and security to their data resources. Over 3000 companies rely on JNetDirect software to provide critical components for their applications and development environments. "
target: Sunergia Group, Inc.
Founded in 2002, Sunergia has built a customer base that includes hundreds of the major university research labs, national research facilities (NIH, NIA, NIMH and NCI) and leading pharmaceutical and biotech companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Replica Analytics Ltd.


read more

Replica Analytics Ltd.

Swoop and IPM.ai

Linguamatics Limited

Meta Inc.

Dropprint Genomics

Cunesoft

Medidata

Qforma, Inc.

Visible Technologies

Qforma, Inc.

SciBite

IO Informatics, Inc.

TEMIS S.A.

FactBio Ltd

NextDocs Corporation

Semantelli

Transcriptic

Dana Solutions

Quantitative Medicine

Sprigley

read more

Replica Analytics Ltd.

read more

Replica Analytics Ltd.

read more

DILIsym Services, Inc.

Simcyp Limited

Pharsight Corporation

Spectral Genomics, Inc.

Vium, Inc.

Dana Solutions

Lixoft

Quantitative Medicine

Leadscope, Inc.

Pirana Software

Adorial

Aureus Sciences

Molegro

Cytel Inc.

Cognigen Corporation

Tessella Ltd.

Archimedes, Inc.

i3 Analytics

Waban Software

Sunergia Group, Inc.

Geography
Matching Companies
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: CNSX:PHGI
 
 
 
 
 
 
 
 
Premier Health Group Inc.
Premier Health is strategically poised to take advantage of business opportunities in the global health care industry. Their subsidiary, HealthVue, is focused on developing proprietary technology to deliver quality healthcare through the combination of telemedicine and artificial intelligence (AI).
year
2021
rev ($mm)
$55.36
EBITDA ($mm)
($10.57)
EBIT ($mm)
($10.89)
Net Income ($mm)
Employees
0
  • drill down
  • watch
Ticker: AIM:CRON
 
 
 
 
 
 
 
 
Cronin Group PLC
Cronin Group PLC provides medical research and development services. The Company focuses on the discovery, development, and manufacture of small molecules and nano-materials utilizing proprietary chemistry. Cronin Group offers its services in the United Kingdom.
year
2018
rev ($mm)
EBITDA ($mm)
($2.29)
EBIT ($mm)
($2.34)
Net Income ($mm)
Employees
25
  • drill down
  • watch
Ticker: LEON
 
 
 
 
 
 
 
 
LION bioscience AG
At the heart of LION’s offering is SRS, the world’s leading integration software for biological data, which seamlessly integrates information from hundreds of publicly available databases with in-house research data.
year
2004
rev ($mm)
$32.30
EBITDA ($mm)
($57.50)
EBIT ($mm)
($76.30)
Net Income ($mm)
Employees
0
  • drill down
  • watch
Ticker: TSXV:DNAX
 
 
 
 
 
 
 
 
BLOCKStrain
BLOCKStrain
BLOCKStrain Technology Corp. has developed the first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry. They are based in Vancouver, BC, Canada.
year
2018
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: TSXV:CRBK
 
 
 
 
 
 
 
 
Carebook Technologies Inc.
Carebook Technologies Inc.
Built on a powerful health platform, Carebook creates highly engaging, customer-centric digital products for pharmacies, insurance providers, governments, businesses, and more. Carebook’s core is science and technology, and its goal is accessible, connected health for everyone.
year
2020
rev ($mm)
$2.87
EBITDA ($mm)
($4.24)
EBIT ($mm)
($4.44)
Net Income ($mm)
Employees
38
  • drill down
  • watch
Ticker: SLP
 
 
 
 
 
 
 
 
Simulations Plus, Inc.
Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software that is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide.
year
2019
rev ($mm)
$35.84
EBITDA ($mm)
$12.38
EBIT ($mm)
$11.28
Net Income ($mm)
$9.11
Employees
109
  • drill down
  • watch
Ticker: POAI
 
 
 
 
 
 
 
 
Predictive Oncology Inc.
Predictive Oncology Inc.
Predictive Oncology Inc. is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. Predictive Oncology operates through five segments which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
year
2019
rev ($mm)
$1.38
EBITDA ($mm)
($13.26)
EBIT ($mm)
($13.71)
Net Income ($mm)
Employees
24
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2020
rev ($mm)
$38.90
EBITDA ($mm)
$6.31
EBIT ($mm)
$5.20
Net Income ($mm)
$3.13
Employees
304
  • drill down
  • watch
Ticker: CHNG
 
 
 
 
 
 
 
 
Change Healthcare Corporation
Change Healthcare Corporation
Change Healthcare is a leading independent healthcare technology company that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system.
year
2020
rev ($mm)
$1,646.91
EBITDA ($mm)
EBIT ($mm)
($155.95)
Net Income ($mm)
Employees
15000
  • drill down
  • watch
Ticker: OMCL
 
 
 
 
 
 
 
 
Omnicell, Inc.
Omnicell, Inc.
Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.
year
2021
rev ($mm)
$914.37
EBITDA ($mm)
$99.36
EBIT ($mm)
$57.86
Net Income ($mm)
$35.01
Employees
2970
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch